REGENERATIVE TISSUE MATRIX
A process for the preparation of a tissue matrix suitable for regenerative repair of tissues, including contacting an isolated connective tissue with an amount of detergent and an amount of disinfectant to significantly reduce at least one of lipids, phospholipids, nucleic acids, major histocompatibility (MHC) antigens, contaminating microorganisms, and endotoxins. The process further provides for less significant reduction in proteoglycan content while retaining the overall structure of the tissue matrix produced. Processing may further include micronizing the tissue matrix. Also, a tissue matrix having a scaffold portion and non-structural portion, collectively structured to promote cellular infiltration, attachment, and proliferation. The tissue matrix may be in the form of a sheet, thick sheet, or micronized. Also, kits including a prepared tissue matrix for use in regenerative repair, and kits for preparing a tissue matrix.
1 . A process for preparing a tissue matrix suitable for regenerative repair of soft tissue, comprising:
isolating a portion of connective tissue for use as the tissue matrix,
contacting the connective tissue with a surfactant,
contacting the connective tissue with a disinfectant,
reducing at least one of proteoglycans, lipids, phospholipids, nucleic acids, and major histocompatibility (MHC) antigens that inhibit cellular infiltration and attachment, and
dehydrating the resultant tissue matrix for storage.
2 . The process as recited in claim 1 further comprising reducing the proteoglycan content of the connective tissue by a range of generally about 30% to 50%.
3 . The process as recited in claim 2 further comprising reducing said proteoglycan content of the connective tissue by no more than about 30%.
4 . The process as recited in claim 1 further comprising reducing the lipid and phospholipid content of the connective tissue by at least 70%.
5 . The process as recited in claim 4 further comprising reducing the lipid and phospholipid content of the connective tissue by a range of about 70% to 95%.
6 . The process as recited in claim 1 further comprising reducing the nucleic acid content of the connective tissue by at least 30%.
7 . The process as recited in claim 6 further comprising reducing the nucleic acid content of the connective tissue by a range of about 30% to 90%.
8 . The process as recited in claim 1 further comprising reducing the major histocompatibility (MHC) antigen I and II content of the connective tissue by at least 85%.
9 . The process as recited in claim 8 further comprising reducing the major histocompatibility (MHC) antigen I and II content of the connective tissue by a range of about 85% to 99%.
10 . The process as recited in claim 1 further comprising removing endotoxins from the connective tissue.
11 . The process as recited in claim 1 further comprising contacting the connective tissue with a chondroitinase enzyme to reduce at least one of proteoglycans, lipids, phospholipids, major histocompatibility antigens (MHC) I and II, and endotoxins in the connective tissue.
12 . The process as recited in claim 11 wherein said chondroitinase enzyme is chondroitinase ABC.
13 . The process as recited in claim 1 further comprising contacting the connective tissue with an alcohol to reduce at least one of lipids and phospholipids in the connective tissue.
14 . The process as recited in claim 13 wherein said alcohol comprises at least one of ethanol, propanol, isopropanol, butanol, glycerol, methanol, pentanol, and combinations thereof.
15 . The process as recited in claim 1 further comprising contacting the connective tissue with an endonuclease to reduce nucleic acids in the connective tissue.
16 . The process as recited in claim 1 further comprising contacting the connective tissue with a lipase enzyme to reduce at least one of lipids, phospholipids, and endotoxins in the connective tissue.
17 . The process as recited in claim 1 wherein said surfactant comprises at least one of an anionic surfactant, a nonionic surfactant, a cationic surfactant, and combinations thereof.
18 . The process as recited in claim 17 wherein said surfactant is further defined as a detergent comprising at least one of an anionic detergent, a nonionic detergent, a cationic detergent, and combinations thereof.
19 . The process as recited in claim 18 wherein said detergent comprises at least one of BRIJ 95 detergent, BRIJ 96 detergent, Tween 20, Triton X100, and combinations thereof.
20 . The process as recited in claim 1 wherein said disinfectant comprises at least one of peracetic acid, chlorine dioxide, hydrogen peroxide, polyvinylpyrolidineiodide, formaldehyde, glutaraldehyde, phenoxyethanol, methylparaben, propylparaben, sodium hydroxymethylglycinate, diazolidinyl urea, DMDM hydantoin, iodopropynyl butylcarbamage, propylene glycol, and combinations thereof.
21 . The process as recited in claim 1 further comprising freeze-drying the resultant tissue matrix.
22 . The process as recited in claim 1 further comprising storing the resultant tissue matrix in a non-aqueous solution.
23 . The process as recited in claim 22 defining the non-aqueous solution as mineral oil.
24 . The process as recited in claim 1 further comprising micronizing the resultant tissue matrix into a plurality of fragments.
25 . The process as recited in claim 24 wherein at least one of said plurality of fragments is in the range of about 100 microns to 300 microns in diameter.
26 . A process for the preparation of a tissue matrix suitable for the repair of soft tissue defects comprising:
isolating a portion of connective tissue for use as the tissue matrix,
contacting the connective tissue with at least one proteoglycan reducing solution;
contacting the connective tissue with at least one phospholipid reducing solution;
contacting the connective tissue with at least one lipid reducing solution;
contacting the connective tissue with at least one nucleic acid reducing solution; and
contacting the connective tissue with at least one major histocompatibility antigen reducing solution.
27 . The process as recited in claim 26 further comprising contacting said connective tissue with at least one endotoxin eliminating solution.
28 . The process as recited in claim 26 defining the connective tissue as comprising at least one of allogenic connective tissue, xenogenic connective tissue, autogenic connective tissue, and combinations thereof.
29 . The process as recited in claim 26 defining the connective tissue as comprising at least one of fascia, skin, dermis, pericardium, periosteum, tendon, ligament, dura, omentum, cartilage, and combinations thereof.
30 . The process as recited in claim 26 further comprising isolating a portion of connective tissue from at least one of a cadaver or a living donor.
31 . The process as recited in claim 26 defining the nucleic acid content as comprising at least one of deoxyribonucleic acids, ribonucleic acids, and derivatives thereof.
32 . The process as recited in claim 26 defining the phospholipid content as comprising at least one of diacylglycerophosphatides, triacylglycerides and derivatives thereof.
33 . The process as recited in claim 26 defining the lipid content as comprising at least one of nonsaponifiable lipids, cholesterols, and derivatives thereof.
34 . A tissue matrix prepared by the process of claim 1 .
35 . A tissue matrix suitable for use in regenerative repair of soft tissue, said tissue matrix comprising:
a scaffold portion structured to provide shape to the tissue matrix, and
a non-structural portion disposed in interspersed relation through at least a part of said scaffold portion,
wherein said scaffold portion and said non-structural portion are collectively structured to promote cellular infiltration, attachment, and proliferation of at least one host cell into the tissue matrix upon implantation or transplantation of the tissue matrix into a host tissue.
36 . The tissue matrix as recited in claim 35 wherein said scaffold portion and said non-structural portion comprise reduced levels of at least one of proteoglycans, lipids, phospholipids, nucleic acids, major histocompatibility (MHC) antigens, and endotoxins.
37 . The tissue matrix as recited in claim 35 wherein at least one of said structural portion and said non-structural portion have been at least partially acellularized.
38 . The tissue matrix as recited in claim 35 further comprising at least one molecular component structured to promote attachment of at least one host cell to said scaffold portion or said non-structural portion.
39 . The tissue matrix as recited in claim 35 further comprising at least one mitogenic factor having inducing capabilities to promote induction of at least one host cell to divide and grow within the tissue matrix.
40 . The tissue matrix as recited in claim 35 further comprising at least one angiogenic factor having inducing capabilities to promote vascularization from the host tissue into at least said non-structural portion.
41 . The tissue matrix as recited in claim 35 further comprising at least one morphogenic factor having inducing capabilities to induce at least one cell within said scaffold portion or said non-structural portion to differentiate into the cellular phenotype of the host tissue.
42 . The tissue matrix as recited in claim 35 wherein said scaffold portion comprises a collagenous structure.
43 . The tissue matrix as recited in claim 35 further comprising at least one endogenous growth factor.
44 . The tissue matrix as recited in claim 35 further comprising at least one endogenous differentiation factor.
45 . A kit for regenerative soft tissue repair, said kit comprising:
a tissue matrix of isolated connective tissue,
said tissue matrix comprising reduced levels of at least one of proteoglycans, lipids, phospholipids, nucleic acids, major histocompatibility (MHC) antigens, and endotoxins,
wherein said tissue matrix is structured to promote cellular infiltration, attachment, and proliferation of at least one host cell into the tissue matrix upon implantation or transplantation of the tissue matrix into a host tissue.
46 . The kit as recited in claim 45 further comprising an amount of transfer solution for transferring said tissue matrix into a host tissue.
47 . The kit as recited in claim 46 wherein said transfer solution comprises at least one of saline, buffered saline, and water.
48 . The kit as recited in claim 45 wherein said tissue matrix comprises a dermal sheet.
49 . The kit as recited in claim 45 wherein said tissue matrix comprises a thick dermal sheet.
50 . The kit as recited in claim 45 wherein said tissue matrix comprises a population of micronized connective tissue.
51 . The kit as recited in claim 50 further comprising an amount of transfer solution for transferring said micronized connective tissue into a host tissue.
52 . The kit as recited in claim 51 further comprising at least one of a needle and syringe.
53 . The kit as recited in claim 52 wherein said syringe is pre-filled with a predetermined amount of micronized connective tissue in a solution.
54 . The kit as recited in claim 45 further comprising instructions of use.
55 . The kit as recited in claim 45 further comprising at least one assay reagent for use in detecting regenerative repair in a tissue.
56 . The kit as recited in claim 55 wherein said at least one assay reagent is structured for use in detecting at least one of cellular infiltration, cellular attachment, cellular proliferation, cellular differentiation, and synthesized matrix materials in a tissue.
57 . The kit as recited in claim 56 wherein said at least one assay reagent comprises at least one of a fluorescent compound, a molecular label, a molecular label substrate, an enzyme, a radioisotope, heavy atoms, a reporter gene, a vector, a luminescent compound, and an antibody.
58 . A kit for processing connective tissue to render a resultant tissue matrix suitable for regenerative repair of soft tissue, said kit comprising:
an amount of a surfactant, and
an amount of a disinfectant.
59 . The kit as recited in claim 58 wherein said surfactant is a detergent.
60 . The kit as recited in claim 59 wherein said detergent comprises at least one of BRIJ 95 detergent, BRIJ 96 detergent, Tween 20, Triton X100, and combinations thereof.
61 . The kit as recited in claim 58 wherein said disinfectant comprises at least one of peracetic acid, chlorine dioxide, hydrogen peroxide, polyvinylpyrolidineiodide, formaldehyde, glutaraldehyde, phenoxyethanol, methylparaben, propylparaben, sodium hydroxymethylglycinate, diazolidinyl urea, DMDM hydantoin, iodopropynyl butylcarbamage, propylene glycol, and combinations thereof.
62 . The kit as recited in claim 58 further comprising an amount of an alcohol.
63 . The kit as recited in claim 62 wherein said alcohol comprises at least one of ethanol, propanol, isopropanol, butanol, glycerol, methanol, pentanol, and combinations thereof.
64 . The kit as recited in claim 58 further comprising an amount of a chondroitinase enzyme.
65 . The kit as recited in claim 64 wherein said chondroitinase enzyme is chondroitinase ABC.
66 . The kit as recited in claim 58 further comprising an amount of an endonuclease.
67 . The kit as recited in claim 58 further comprising an amount of a lipase.
68 . The kit as recited in claim 58 further comprising an amount of an endotoxin reducing solution.
69 . The kit as recited in claim 58 further comprising a storage solution.
70 . The kit as recited in claim 69 wherein said storage solution comprises a non-aqueous solution.
71 . The kit as recited in claim 70 wherein said storage solution is mineral oil.
72 . The kit as recited in claim 58 further comprising instructions of use.
73 . The kit as recited in claim 58 further comprising at least one assay reagent for use in detecting regenerative repair in a tissue.
74 . The kit as recited in claim 73 wherein said at least one assay reagent is structured for use in detecting at least one of cellular infiltration, cellular attachment, cellular proliferation, cellular differentiation, and synthesized matrix materials in a tissue.
75 . The kit as recited in claim 74 wherein said at least one assay reagent comprises at least one of a fluorescent compound, a molecular label, a molecular label substrate, an enzyme, a radioisotope, heavy atoms, a reporter gene, a vector, a luminescent compound, and an antibody.